Please assess the completion status of the following clinical trial:

Trial Title: Docetaxel, Doxorubicin (A), Cyclophosphamide (C) (TAC) vs 5-Fluorouracil, A, C (5FAC) Breast Cancer Adjuvant Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent~* Operable breast cancer patients (T1-T3) with negative axillary lymph nodes (10 axillary nodes dissection) and high risk criteria according to St. Gallen consensus criteria.~* Histologically proven breast cancer. Interval between surgery and registration is less than 60 days.~* Definitive surgical treatment must be either mastectomy, or breast conservative surgery. Margins of resected specimen from surgery must be histologically free of invasive adenocarcinoma and ductal carcinoma in-situ (DCIS). Lobular carcinoma in-situ is not considered as positive margin.~* Patients without proven metastatic disease.~* Estrogen and progesterone receptors performed on the primary tumour prior to randomization.~* Age between 18 years and 70 years.~* Karnofsky performance status index \> 80 %.~* Adequate hepatic, renal and heart functions.~* Adequate hematology levels.~* Negative pregnancy test~Exclusion Criteria:~* Prior systemic anticancer therapy for breast cancer (immunotherapy, hormonotherapy, chemotherapy).~* Prior anthracycline therapy or taxoids (paclitaxel, docetaxel) for any malignancy.~* Prior radiation therapy for breast cancer.~* Bilateral invasive breast cancer.~* Pregnant, or lactating patients.~* Patients of childbearing potential must implement adequate non-hormonal contraceptive measures during study treatment .~* Any T4 or N1-3 or M1 breast cancer.~* Pre-existing motor or sensory neurotoxicity of a severity grade 2 by NCI criteria.~* Other serious illness or medical condition~* Past or current history of neoplasm other than breast carcinoma.~* Ipsilateral ductal carcinoma in-situ (DCIS) of the breast.~* Lobular carcinoma in-situ (LCIS) of the breast.~* Chronic treatment with corticosteroids unless initiated \> 6 months prior to study entry and at low dose~* Concurrent treatment with ovarian hormonal replacement therapy. Prior treatment should be stopped before study entry.~* Definite contraindications for the use of corticosteroids.~* Concurrent treatment with other experimental drugs.~* Participation in another clinical trial with any investigational not marketed drug within 30 days prior to study entry.~* Concurrent treatment with any other anti-cancer therapy.~* Male patients.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Arm A: FAC (Type: ACTIVE_COMPARATOR): FAC (5-fluorouracil, doxorubicin, cyclophosphamide): 5-fluorouracil 500 mg/m2 iv on day 1, each 3 weeks, in combination with doxorubicin 50 mg/m2 iv and cyclophosphamide 500 mg/m2 iv
- Arm B: TAC (Type: EXPERIMENTAL): TAC (docetaxel, doxorubicin, cyclophosphamide): Docetaxel 75 mg/m2 iv on day 1, each 3 weeks, in combination with doxorubicin 50 mg/m2 iv and cyclophosphamide 500 mg/m2 iv

Based on this trial design, predict the completion outcome and termination type (if applicable).